|
|
|
Abeona Therapeutics Inc (NASDAQ: ABEO) |
|
Abeona Therapeutics Inc
Officers & Directors
Vishwas Seshadri President, Chief Executive Officer and Director - (Principal Executive Officer) Christine Silverstein Director Faith L. Charles Director Leila Alland Director Michael Amoroso Director, Chairman of the Board Mark J. Alvino Director Donald A. Wuchterl Director Joseph Vazzano Chief Financial Officer - (Principal Financial and Accounting Officer) ,
Abeona Therapeutics Inc currently has 226 employees.
News about Abeona Therapeutics Inc Key Personnel |
In the fast-evolving sphere of biopharmaceuticals, maintaining a competitive edge is crucial, especially for companies like Abeona Therapeutics Inc. (Nasdaq: ABEO), which is devoted to developing groundbreaking gene therapies aimed at treating rare genetic disorders. Recently, the company announced a strategic move in the form of equity awards granted to new non-executive employees, reflecting its commitment to attracting and retaining talent even amidst financial challenges. A Strategic Approach to Employee Inducements On December 2, 2024, Abeona Therapeutics disclosed that it had granted equity awards to newly onboarded employees, a decision that underscores its adherence to Nasdaq Listing Rule 5635(c)(4)....
|
Abeona Therapeutics Faces Financial Headwinds While Pursuing Gene Therapy Approval: A Close Look at Recent Developments and Employee InducementsAbeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company focused on developing innovative gene therapies, has recently announced the granting of equity awards to new non-executive employees as part of their efforts to revolutionize treatment for rare genetic disorders. This decision was made in accordance with Nasdaq Listing Rule 5635(c)(4) and reflects the company s ongoing commitment to attracting and retaining talent despite its challenging financial landscape. Recent Employee Inducement GrantsOn November 1, 2024, Abeona Therapeutics rep...
|
Abeona Therapeutics: Navigating Financial Turbulence in the Quest for Gene Therapy ApprovalCLEVELAND — In the high-stakes world of biotech, few situations are as precarious as the race for the next groundbreaking treatment. Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company, finds itself at this critical juncture, recently resubmitting its Biologics License Application (BLA) for its investigational gene therapy, prademagene zamikeracel (pz-cel), to the U.S. Food and Drug Administration (FDA). The therapy aims to treat patients suffering from recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder, but it comes against a backdrop of significant financ...
|
Abeona Therapeutics Secures $50 Million Credit Facility to Accelerate Growth
CLEVELAND, Jan. 08, 2024 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading biopharmaceutical company focused on developing transformative gene and cell therapies, announced today a major milestone in its financial strategy. The company has successfully secured a $50 million credit facility with the Avenue Venture Opportunities Fund, L.P. This new credit agreement, with a term of three and a half years, will provide Abeona Therapeutics with the necessary capital to fuel its ongoing research and development efforts.
Under the terms of the credit facility, the funding will be available in multiple tranches. The first tranche...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
